Using a recombinant retrovirus with ecotropic envelope we have achieved high efficiency of transduction of endothelial cells in the vasculature of subcutaneous xenografts arising from the co-injection of tumour cells and irradiated virus producers. We have used this experimental system to assess the efficacy of the herpes simplex virus-thymidine kinase (HSV-tk)/ganciclovir (GCV) prodrug activation system in anti-vascular therapy. Treatment of KSY-1 xenografts with HSV-tk transduction in the vascular compartment with the Sphase-dependent drug GCV resulted in extensive haemorrhagic necrosis, indicative of vascular damage. Therapeutic potential in tumours with transduced endothelial cells comprising 5% or less of the total tumour mass was similar to that of tumours with HSV-tk expression in over 46% of
Introduction
It is well established that tumours need a blood supply for growth and metastasis. Whether tumours grow to a very small diameter as avascular masses 1, 2 or need to coopt existing vessels for their initial growth, 3 neovascularization controlled by a large number of angiogenic factors and inhibitors of angiogenesis is necessary for tumour progression and metastasis. Anti-angiogenic drugs such as TNP-470, and antibodies against angiogenic factors or their receptors (eg VEGF and bFGF) can all inhibit tumour growth, 4, 5 (reviewed in Ref. 6 ), whereas endogenous inhibitors of angiogenesis such as angiostatin and endostatin can also revert the growth of established experimental tumours to their dormant state. 7, 8 While anti-angiogenic therapies inhibit complex interactions between tumour cells and stromal cells by influencing the balance between promoters and inhibitors of angiogenesis, anti-vascular therapy aims to destroy existing blood vessels and consequently the tumour cells that they support. In an experimental subcutaneous tumour model, initiating thrombosis by targeting human tissue factor to an induced marker on the surface of endothelial cells resulted in tumour regression. 9 Coupling doxorub-tumour cells. GCV treatment of animals bearing MDA-MB-361 breast carcinoma, SW620 and CACO2 colon carcinomas with HSV-tk expression in the vascular compartment also resulted in reduced tumour growth. We conclude that HSV-tk/GCV prodrug activation is an effective strategy for eradicating tumour vasculature, and that direct targeting of proliferating endothelial cells in established vasculature results in reduced tumour growth. The therapeutic potential observed with the slow-growing CACO2 colon and MDA-MB-361 breast carcinomas supports the notion that anti-vascular therapy targeted at proliferating endothelium is likely to prove efficacious in human cancers that generally grow at a lower rate than experimental tumours. Gene Therapy (2001) 8, 913-920.
icin to a peptide that homes to angiogenic blood vessels in tumours enhanced the antitumour activity of the drug and reduced its toxicity. 10 Targeting tumour vasculature with a peptide containing both apoptotic and endothelial homing domains also resulted in reduced tumour burden and improved survival of mice bearing subcutaneous xenografts.
11
Genetic approaches are favourable when considering targeting strategies, as they offer the potential to incorporate multiple levels of control such as delivery and gene expression, in order to achieve therapeutic specificity. 12 Retroviral vectors are promising candidates for delivering genes to angiogenic blood vessels in tumours because of their dependence on cell division for integration and expression, 13 providing one level of specificity. Numerous strategies have been proposed for eradicating tumour vasculature including the delivery of angiogenic antagonists, genes that induce apoptosis, or genes that activate toxic prodrugs.
14 There have been several reports of prodrug activation for endothelial cell killing in vitro. Occasional endothelial cell transduction has been observed in vivo following stereotactic injection of virus-producing cells into established brain tumours, prompting the authors to suggest a vascular component to the bystander effect they observed. 15 However, the development of gene therapy approaches to target tumour vasculature has so far been compromised by the lack of in vivo models to assess the efficacy of potential strategies, while the issues of specificity and delivery of retroviral vectors are being addressed. 16 The low infectivity of endothelial cells by recombinant retroviruses in vitro has also been a considerable concern.
Here, we have used an ecotropic retrovirus to achieve selective transduction of host-derived vasculature in subcutaneous xenografts arising from the co-injection of tumour cells and irradiated virus producers. We have used this model that achieves high efficiency of transduction of endothelial cells in the tumour vasculature to assess the potency of the HSV-tk/GCV prodrug activation system in anti-vascular therapy. We have monitored the growth and observed the histological appearance of treated KS Y-1 Kaposi's sarcoma, and extended the study to include MDA-MB-361 breast, and SW620 and CACO2 colorectal carcinomas.
Results
Selective transduction of host-derived vasculature or tumour cells in subcutaneous xenografts using ecotropic and RD114 enveloped viruses Recombinant retroviruses bearing the ecotropic envelope (infectious for murine but not human cells) or the feline endogenous virus RD114 envelope (infectious for human but not murine cells) were used to direct ␤-galactosidase reporter gene expression to the vascular or tumour cell compartments of tumours grown subcutaneously in nude mice. In order to achieve a high efficiency of transduction tumour cells were co-injected with irradiated virus producers. Tumours were excised 14 days following subcutaneous injection and ␤-galactosidase expression was detected by means of histochemical staining. Expression was observed in endothelial cells lining blood vessels in tumours with ecotropic transduction, arising from the coinjection of KS Y-1 cells and ecotropic virus producers (Figure 1a, b) . In tumours arising from the co-injection of KS Y-1 cells and RD114 virus producers transduction was confined to the tumour cell compartment (Figure 1c ). There were no ␤-galactosidase-expressing cells detectable within the tumour cell compartment of tumours with ecotropic transduction, or in the vascular compartment in tumours with RD114 transduction, confirming that the irradiated virus producers had cleared from the tumour mass. Selective transduction of host-derived vasculature was similarly demonstrated for the tumour cell lines SW620, CACO2 and MDA-MB-361 (data not shown).
In vitro analysis of HSV-tk viruses Retroviral vectors bearing RD114 or ecotropic envelopes were generated for selective delivery of HSV-tk to the a b c tumour cell compartment or host-derived vasculature as described earlier. The ecotropic and RD114 HSV-tk viruses were tested in vitro for their activity and tropism using 3T3, KS Y-1 and TE671 as target cells. An amphotropic HSV-tk virus was used in these experiments as a control, capable of infecting all cell types. Following infection with virus supernatants from high-titre pro-ducer clones, GCV was administered for 5 days and the viability of target cells was determined in MTT colorimetric assays ( Figure 2 ). The multiplicity of infection (MOI) for each target cell type was estimated by quantitative Southern blot analysis carried out in parallel using HSV-tk plasmid copy number equivalents. There was efficient killing in response to GCV treatment of 3T3 fibroblasts infected with the ecotropic HSV-tk virus. The better survival of KS Y-1 cells infected with the RD114 HSV-tk virus can be attributed in part to their lower infectibility in vitro. However, KS Y-1 cells are also relatively resistant to GCV treatment, since there was threefold better survival of KS Y-1 compared with TE671 cells when those were infected at similar multiplicities (0.8 and 0.9, respectively) using the amphotropic HSV-tk virus.
Endothelial cell death and reduced tumour growth in response to GCV treatment of KS Y-1 tumours with ecotropic HSV-tk transduction KS Y-1 cells were co-injected with irradiated ecotropic or RD114 HSV-tk virus producers subcutaneously in nude mice in order to generate tumours with selective transduction in the stromal or tumour cell compartments as described earlier. Groups of animals bearing tumours of similar sizes were treated with GCV or water as control starting 14 days following injection. Proliferation of a high proportion of cells in both compartments in tumours at this stage was demonstrated by immunohistochemical staining for PCNA expression (data not shown), confirming their sensitivity to the S-phase-dependent toxicity of GCV. Some tumours were excised untreated for determination of transduction efficiency by quantitative Southern blotting. The calculated MOIs of 0.27, 0.41 and
Figure 2 In vitro tropism and activity of HSV-tk viruses bearing amphotropic, RD114 and ecotropic envelopes. Cells were infected with amphotropic (neat), RD114 or ecotropic (1:10 dilution) HSV-tk viruses from high titre producer clones as described in Materials and methods. Following infection cells were plated in 96-well plates and treated with 10 g/ml GCV for 5 days. Viabilty of transduced cells following treatment was determined by MTT colorimetric assays and this is shown as % of that of untreated cells. The viabilty of nontransduced cells treated at this concentration of GCV was over 90%. Values were determined in duplicate and are shown as means. The multiplicity of infection (MOI) of transduced cells was calculated by quantitative Southern blot analysis of vector copy number, and values are shown above the corresponding bars.
Gene Therapy 0.52 of tumours with RD114 transduction (Figure 3a) correspond to tumour cell transduction efficiencies of 33%, 47% and 57% (average ± s.e. = 46% ± 7%) after the proportion of the mouse DNA component is taken into consideration (19.2, 12.8 and 8.2%, respectively in these tumours; Figure 3b) . Since it was possible that a smaller proportion of tumour cells were transduced with multiple copies of the gene, the percentage of expressing cells was also estimated by staining for the myc tagged HSVtk following re-establishment of tumour cells in culture, and this was in agreement with the above figures (data not shown). Similarly, the calculated MOI of approximately 0.05 for tumours with ecotropic transduction (Figure 3a) corresponds to transduction efficiencies of 14% and 21% of stromal cells after the amount of mouse tissue is taken into consideration (Figure 3b) . The differences in the amount of mouse tissue amongst different tumours were size related, with smaller KS Y-1 tumours bearing a higher proportion of host-derived component (data not shown). We estimated that at the start of GCV treatment endothelial cells accounted for less than 50% of host stroma (other cells being untransduced stromal fibroblasts), suggesting that up to 40% of endothelial cells were transduced in those tumors. In agreement with the above, the percentage of transduced endothelial cells in sections from KS Y-1 tumours with ␤-galactosidase transduction in the vascular compartment was of comparable order ( Figure 1) .
The mean growth rates of tumours with ecotropic HSV-tk transduction over 3 weeks of GCV treatment are shown in Figure 4 . Treated tumours grew significantly slower than untreated controls. Reduced tumour growth was observed in all treated tumours for approximately 2 weeks and for four of seven tumours for approximately 18 days (Figure 4a ). Reduced tumour growth was consistently observed in three independent experiments. The therapeutic effect in tumours with HSV-tk-transduced vasculature comprising 5% or less of the total tumour mass was similar to that of tumours with HSV-tk expression in 46% of the tumour cell compartment (Figure 4b ). In sections of tumours with ecotropic transduction extravasation of red blood cells could be seen from day 4 of GCV treatment (data not shown). Extensive haemorrhagic necrosis was observed at later stages of treatment, while tumours eventually grew from a thin vascularised rim measuring less than 10% of the tumour diameter ( Figure 5 ). In tumours with transduction in the tumour cell compartment tumour cell damage was partment following GCV treatment confirmed that the reduced growth was at least partly a consequence of vascular damage, although HSV-tk endothelial cell expression may also have had a bystander effect in surrounding tumour or stromal cells.
Reduced tumour growth in response to GCV treatment of MDA-MB-361 breast and SW620 and CACO2 colon carcinomas with ecotropic HSV-tk transduction The efficacy of HSV-tk/GCV was further investigated in human breast and colorectal carcinomas grown as xenografts in nude mice. MDA-MB-361 breast carcinoma arising from the co-injection of tumour cells and irradiated ecotropic virus producers showed reduced growth in response to GCV compared with controls ( Figure 6a) . Determination of HSV-tk copy number showed that transduction was highly efficient in this tumour model (1.7-6.5 copies per cell; Figure 6b ). Following GCV treatment there was over five-fold reduction in HSV-tk copy number (Figure 6b ). This reduction in copy number was not accompanied by reduction in the proportion of mouse tissue in these tumours, suggesting that neovascularisation had taken place. SW620 and CACO2 were chosen as fast and slow colorectal carcinomas, respectively. Tumour cells were co-injected with irradiated eco-
Figure 6 Eradication of HSV-tk-expressing cells and reduced growth rate in response to GCV treatment of subcutaneous MDA-MB-361 xenografts with ecotropic HSV-tk transduction. (a) Growth rates of MDA-MB-361 tumours. Tumour cells were co-injected with irradiated ecotropic HSV-tk virus producers. GCV was administered intraperitoneally at 100 mg/kg body weight starting 14 days after subcutaneous injection. Control animals received water. Days shown are after the beginning of treatment. Data are means (n); bars s.e. (b) Southern blot analysis of treated and untreated MDA-MB-361 tumours with ecotropic HSV-tk transduction. Genomic DNA was isolated from treated and control tumours and digested with XbaI. Plasmid copy number equivalents added to DNA from uninfected cells were used for quantitation of signals.
Gene Therapy tropic virus producers as described earlier. As in KS Y-1, transduction efficiencies in these tumors were of the order of 5% or less (data not shown). Treated SW620 and CACO2 tumours grew significantly slower than untreated controls (Figure 7) . The effect was more marked for the slower growing CACO2 tumours. SW620 tumors in which 5% of the tumour mass was composed of HSV-tk tumour cells did not show significant growth reduction (data not shown), supporting the importance of endothelial cells rather than a simple drug-related bystander effect for the response seen.
Discussion
We have sought to assess the efficacy of HSV-tk/GCV prodrug activation as a targeting strategy aimed at the vascular compartment of tumours. Since issues of intravenous delivery of retroviral vectors to tumours are currently being addressed, we have used a simple model of subcutaneous co-injection of tumour cells and irradiated virus producers to achieve high efficiency of transduction. In contrast to the localised transduction that results from direct injection of virus supernatant into tumours, high efficiency of tranduction throughout the tumour mass can be achieved in this model. 17 The RD114 and ecotropic enveloped viruses used in this study exploit the different tropisms of these natural viral envelope proteins to achieve selective transduction of tumour cells or hostderived vasculature in xenografted human tumours, allowing targeting strategies to be tested under optimal conditions of transduction.
Transduction in the subcutaneous co-injection model takes place during the initial phase of tumour growth. We confirmed by histochemical staining that irradiated producers disappear from the tumour mass within 2 weeks following subcutaneous injection. Proliferating endothelium transduced early during tumour development persists in the vasculature of larger tumours. The extent to which nontransduced endothelial cells and other stromal cells are recruited at later stages is likely to depend on the tumour model and this is probably reflected in the differences in transduction efficiencies we observed in different tumours (eg between KS Y-1 and MDA-MB-361 tumours) at the time of sampling. We estimated that in KS Y-1 tumours with HSV-tk transduction in the host vasculature the number of transduced cells represented approximately 5% of the total cellular mass of the tumour. Treatment with GCV resulted in endothelial cell death early during treatment, followed by haemorrhagic necrosis associated with blood vessel damage. Treated tumours with ecotropic HSV-tk transduction grew significantly slower than untreated controls. The survival of over half of these tumours was comparable with that of tumours with HSV-tk transduction of 46% cells in the tumour cell compartment. Targeting endothelial cells may therefore be a more effective strategy for some tumours, since a smaller number of cells need to be targeted.
Growth of GCV-treated KS Y-1 tumours with transduction in the vascular compartment formed from a thin viable rim representing less than 10% of the tumour diameter. The growth of tumours from a thin viable rim following anti-vascular treatment has previously been reported in surviving tumours after induction of thrombosis in tumour blood vessels, 9 and in response to treatment with tubulin destabilising agents such as combretastatin, known to cause vascular shut-down. 18, 19 These and our results suggest that when considering clinical protocols using targeted vectors currently under development, it may be necessary to combine anti-vascular therapies with tumour cell-directed treatments such as conventional radiotherapy or chemotherapy, 20, 21 although the HSV-tk/GCV prodrug activation system is expected to be significantly more efficacious in the presence of an immune component. [22] [23] [24] [25] Reduced growth in response to GCV treatment was also observed for breast MDA-MB-361, colon SW620 and CACO2 carcinomas with ecotropic HSV-tk transduction, the effect being more marked for the slower growing MDA-MB-361 and CACO2 tumours. The variability in the potency of response among different tumour lines is likely to be associated with differences in transduction efficiencies (there was much higher transduction efficiency in MDA-MB-361 compared with other tumours that correlated with better differential between treated and untreated MDA-MB-361 tumours). The observed effect of GCV treatment on tumour growth is also expected to depend upon the intrinsic proliferative potential of the tumour cells, as well as how effectively each tumour line recruits new vasculature following the destruction of HSV-tk-expressing blood vessels.
The susceptibility to the S-phase-dependent toxicity of GCV of MDA-MB-361 and CACO2 tumours with endothelial HSV-tk transduction suggests that despite the slow growth rate of these tumours, endothelial cells in the vascular compartment proliferate, possibly at a higher rate than tumour cells. High endothelial cell proliferation in slow growing tumours may be balanced by apoptosis and vascular regression. 26 Studies have confirmed that endothelial cells in human cancers also have a higher proliferative index compared with other organs despite the much slower growth rate of human tumours compared with experimental ones. [27] [28] [29] [30] These observations and our findings support the notion that anti-vascular therapy targeted at proliferating endothelium is likely to prove efficacious in human tumours.
In summary, we have transduced tumour vasculature with HSV-tk in KS Y-1 Kaposi's sarcoma, MDA-MB-361 breast carcinoma, SW620 and CACO2 colorectal carcinomas, and have achieved good therapeutic potential in response to GCV treatment. To our knowledge this is the first demonstration that prodrug activation is an effective anti-vascular approach. Furthermore, the in vivo model of subcutaneous xenografts arising from the co-injection of tumour cells and ecotropic virus producers can be used for rapid evaluation of targeting strategies aimed at the vascular compartment of tumours.
Materials and methods
Cell lines TE671 (human rhabdomyosarcoma), 3T3 (mouse fibroblasts), SW620 and CACO2 colorectal carcinomas, MDA-MB-361 breast carcinoma 31 and Kaposi's sarcomaderived KS Y-1 32 were maintained in DMEM supplemented with 10% FCS. TE-FLY-A8, TE-FLY-Mo and TE-FLY-RD amphotropic, ecotropic and RD114 retroviral packaging cell lines (F-L Cosset, unpublished) were similarly maintained.
Construction of HSV-tk retroviral vectors
The thymidine kinase gene was amplified by PCR from plasmid pG1TK1SVNa (Gene Therapy Inc., Gaithersburg, MD, USA) using the forward primer 5′-GAGGATCCAC CATGGAGCAGAAGCTTATCTCCGAGGAGGATCTGG CTCG incorporating BamHI and NcoI restriction sites, a Kozak consensus sequence 33 and a human myc epitope tag for expression at the amino terminus. Reverse primer was 5′-GAGGATCCTCAGTTAGCCTCCCCCATC incorporating a BamHI restriction site. The amplified product was cloned into the BamHI site of pBS for DNA sequencing and subsequently subcloned as an NcoI/BamHI fragment into the retroviral vector MFG-S −34 to generate the vector MFG-S − .TK.
Recombinant retroviruses
The packaging cell line TE-FLY-A8, a TE671-based equivalent of FLY-A13 35 was used to generate amphotropic thymidine kinase retrovirus following CaPO 4 -mediated co-transfection of pMFG-S − .TK (10 g) with plasmid pSV 2 neo (0.5 g) containing a neomycin resistance cassette. Stable transfectants were selected in 1 mg/ml G418. Virus was harvested following overnight incubation of confluent monolayers in fresh medium, and filtered (0.45 m). Target cells growing on coverslips were infected with virus supernatant in the presence of 8 g/ml polybrene for 4-6 h. Culture medium was changed and cells were stained 2-3 days later using the 9E10 antibody (Sigma) against the myc epitope tag to identify virus-producing clones. A-TK16, a high-titre amphotropic TK virus was obtained from the producer clone with the highest transduction efficiency in 3T3 cells following infection and quantitation of proviral copy number by Southern blot analysis (see below). Ecotropic and RD114 viruses (Mo-TK2 and RD114-TK6) were generated by infecting TE-FLY-Mo and TE-FLY-RD114 packaging cell lines with high-titre amphotropic virus supernatant, followed by selection in 1 mg/ml G418 of hightitre producer clones as described above. High-titre amphotropic and RD114 MFGnlslacz viruses were from the producer clones TELCeB6AF and TELCeB6RDF respectively, 35 high-titre ecotropic virus was from an equivalent producer clone (F-L Cosset, unpublished).
GCV sensitivity assays
Target cells were infected as described above and plated in 96-well plates at a density of 3 × 10 3 cells per well 2-3 days following infection. The following day GCV (Cymevene; Roche, Welwyn Garden City, UK) was added to the medium at varying concentrations. Cell viability was assessed after 5 days of treatment by MTT colorimetric assays. 
